Podcasts about abbv

In this week's episode of Dividend Talk we kick off with Kimberly-Clark's surprise move to buy Kenvue, asking if it's a smart acquisition or a future balance-sheet headache. Then we review Q3 earnings from Novo Nordisk, Wolters Kluwer, and Ahold Delhaize, three European dividend powerhouses facing very different challenges.Novo Nordisk's obesity drugs, valuation reset, and dividend safety dominate the discussion, while Wolters Kluwer's high-PE sell-off and the impact of AI on research businesses spark debate on fair value and buybacks. We also look at Snap-on's double-digit dividend hike and Simon Property Group's steady income growth for REIT investors.Later, we revisit our “Monthly Dividend Portfolio” challenge from 2022, checking how picks like Altria, AbbVie, Johnson & Johnson, Realty Income, Shell, and Texas Instruments performed with lessons on dividend growth, yield, and diversification.In the listener Q&A, we cover:Dividend tax strategies and EU exit taxes How to handle rising wealth taxes as a dividend investor Fair-value analysis vs Morningstar valuations Our take on Volkswagen, General Mills, GreenCoat UK, ExxonMobil vs Chevron, and the global renewable-energy transition Thoughts on Unilever's upcoming Magnum spinoff SEE YOU ON THE INSIDE!!Tickers discussed: KMB, KVUE, NVO, LLY, PFE, WKL.AS, AD.AS, SNAP-ON, SPG, MO, ABBV, JNJ, O, TXN, SHEL, GIS, XOM, CVX, UKW.LJoin us:[Facebook] – Https://www.facebook.com/groups/dividendtalk⁠[Twitter] – @DividendTalk_ , @European_DG[Discord] – ⁠https://discord.gg/nJyt9KWAB5⁠[Premium Services] – ⁠https://dividendtalk.eu/download-your-free-samples/⁠[Malmo Meetup] – ⁠https://t.co/STgV1nMWKj

We will discuss how falling birth-rates are becoming more than just a social issue because they are intertwined with economic systems and capitalist assumptions. Today's Stocks & Topics: The Campbell's Company (CPB), Market Wrap, Babies, Capitalism & a Demographic Crossroads, Alexandria Real Estate Equities, Inc. (ARE), Panasonic Holdings Corporation (PCRHY), A-I might replace Junior Bankers, Gold and Uranium Sectors, AbbVie Inc. (ABBV), Vertex Pharmaceuticals Incorporated (VRTX), A-I Financial Models.Our Sponsors:* Check out Gusto: https://gusto.com/investtalk* Check out Progressive: https://www.progressive.com* Check out TruDiagnostic and use my code INVEST for a great deal: https://www.trudiagnostic.comAdvertising Inquiries: https://redcircle.com/brands

Arthur Wong examines AbbVie (ABBV) following the healthcare company's earnings beat in its 3Q. He discusses the pharmaceutical pipeline, its oncology segment and current offerings like its autoimmune medication Humira. Arthur discusses the relationship between weaker consumer sentiment and patients willingness to spend on expensive medical treatments. He also talks about the industry trend to negotiate lower drug-costs with the Trump administration. He says tariffs and "MFN" Pricing (Most Favored Nation) are the biggest headwinds for pharmaceutical companies.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about

S&P Futures are pointing lower this morning as investors digest a wave of earnings, Fed commentary, and geopolitical updates. Mega-cap tech continues to deliver strong margins, though Microsoft's softer PC outlook weighed on its guidance. Fed Chair Jerome Powell struck a hawkish tone in yesterday's press conference, signaling that a December rate cut is not a foregone conclusion. Meanwhile, U.S.–China talks wrapped up as expected, easing trade tensions with no surprises. We'll also touch on YouTube's expiring agreement with Disney, the FDA's push to streamline biologic drug testing, and the latest corporate movers — from GOOG and LLY to META, MSFT, and MRK. After the bell, all eyes turn to Apple, Amazon, Coinbase, Reddit, and Roku, with ABBV, CVX, and XOM set to report tomorrow morning.

3Q earnings season is looking “pretty good” so far, says Don Nesbitt. He notes that analysts have been revising their estimates upwards for “the first time in about four years.” He likes AbbVie (ABBV), which he expects to beat earnings next week, PNC Financial (PNC), where he sees a “great buying opportunity” after they fell on earnings, and Linde (LIN), a “leader in the gas area” that is critical for industrial expansion.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

David Darst looks at the potential Fed Chair nominees and why he thinks Scott Bessent wouldn't take the position. He looks at historical rate cutting cycles and “fever and fervor” in the markets, particularly in AI. He expects earnings to be a market driver next year. David examines his stock picks from March, including GOLD, EL, and ABBV, and brings some new names: Verizon (VZ), Pfizer (PFE), and a gold miner ETF (GLD).======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Some drug stocks are cheap but is it another fake out? (0:30) - Can You Find Strong Value Investments In Drug Stocks Right Now? (3:40) - Breaking Down The Recent Industry Performance (9:00) - Tracey's Top Stock Picks (30:00) - Episode Roundup:  PFE, MRK, ABBV, LLY, NVO

Some drug stocks are cheap but is it another fake out? (0:30) - Can You Find Strong Value Investments In Drug Stocks Right Now? (3:40) - Breaking Down The Recent Industry Performance (9:00) - Tracey's Top Stock Picks (30:00) - Episode Roundup:  PFE, MRK, ABBV, LLY, NVO Podcast@Zacks.com

Starting in 2026, workers aged 50 and older who earned over $145,000 in the prior year will be required to make their 401(k) catch-up contributions on an after-tax Roth basis (a key tax shift mandated by the SECURE 2.0 Act). Today's Stocks & Topics: Trane Technologies plc (TT), Circle Internet Group (CRCL), Market Wrap, Roth or Bust: The $145K 401(k) Catch-Up Rule Change for 2026, Schlumberger Limited (SLB), Zebra Technologies Corporation (ZBRA), Alternative Investments, AbbVie Inc. (ABBV), Gold.Our Sponsors:* Check out Anthropic: https://claude.ai/INVEST* Check out Gusto: https://gusto.com/investtalk* Check out TruDiagnostic and use my code INVEST for a great deal: https://www.trudiagnostic.comAdvertising Inquiries: https://redcircle.com/brands

This week on Dividend Talk, Derek is joined by Jeremy from Dividend Stockpile to explore some of the biggest Megatrends shaping our investing future. We cover the opportunities and risks in infrastructure, clean energy, technology, and healthcare, and how dividend investors can position themselves for the next decade and beyond.You'll hear about recent dividend news from Interface (TILE) and Agree Realty (ADC), how US and European infrastructure approaches differ, why utilities like Iberdrola (IBE.MC) and Enel (ENEL.MI) stand out, and how tech giants Meta (META), Alphabet (GOOG), and Microsoft (MSFT) fit into the AI megatrend. We also look into healthcare innovation, options income strategies, and favourite finance content creators.Tickers Mentioned: TILE, ADC, O, BAM, BIP, NEE, DUK, ED, IBE.MC, ENEL.MI, ABB, DG.PA, META, GOOG, MSFT, GE, CWEN, ASML.AS, SAP, MDT, MRK, ABBV, NVO, LLY, ROG.SW, SNY, SYK, ABT, BDX, RMD, STRCChapters:00:00 – Introduction & Guest Welcome02:52 – Company News: Interface & Dividend Increases05:41 – Agree Realty & REIT Quality08:43 – Understanding Megatrends11:51 – Infrastructure as a Megatrend29:06 – Clean Energy Transition39:31 – The Rise of Technology & AI46:51 – Healthcare Opportunities01:04:06 – Options Income Strategies & High Yield Ideas01:20:06 – Favorite Finance Content Creators & Closing RemarksGet a free sample of our premium dividend newsletter! Stay ahead of the market with in-depth stock analysis here: https://dividendtalk.eu/download-your-free-samples/ Stay Updated:Twitter - @DividendTalk_Twitter - @European_DGIJoin our Facebook Community - Dividend Talk Facebook GroupJoin our Discord group - https://discord.gg/nJyt9KWAB5

In this week's episode of Dividend Talk, we kick off with our Q2 performance review , looking at how our dividend portfolios fared, what we bought, sold, and learned over the past quarter.  We also dive into three big names making headlines: Wolters Kluwer's sharp share price drop and the fear of AI disruption, Novo Nordisk's earnings and competition with Eli Lilly, and UnitedHealth's reduced outlook.  Along the way, we cover dividend hikes and cuts from around the globe, have some laughs over corporate slogans, and answer a packed list of listener questions ranging from sector risks to portfolio construction. SEE YOU ON THE INSIDE!! Tickers discussed: WKL.AS, NVO, LLY, UNH, HEIA.AS, NN.AS, AD.AS, ITW, CLX, AWR, WHR, LGEN.L, MRK, LVMH.PA, TGT, LYB, NKE,CVX, HPQ, MSFT, SHEL, BTI, BAM, BAES.L, HORNB.BR, UPS, PEP, CCOI, ORA.PA,ASR.AS, ASML.AS, UL, GLB.IR, KRZ.F, KESKOB.HE, KNEBV.HE, SAMPO.HE, AGE.BR, XIOR.BR,ASC.BR, SHL.DE, DEF.F, NVO-B.CO, VICI, RY, DOL.TO, FTS.TO, UKW.L, VOLVB.ST,INVE-A.ST, INVE-B.ST, SEB-A.ST, SWED-A.ST, HAND-B.ST, SHELL.AS, VIE.PA, O,SECUB.ST, ABBV, BAYN.DE.  Join us :[Facebook]  - Https://www.facebook.com/groups/dividendtalk[Twitter] -   @DividendTalk_    ,  @European_DG[Discord] - https://discord.gg/nJyt9KWAB5[Premium Services] - https://dividendtalk.eu/how-it-works

Mike Shorr walks through a pair of stocks he sees set up for a swing breakout: AbbVie (ABBV) and Etsy Inc. (ETSY). For both, he demonstrates an example options trade using a call spread. Later, he also looks at Vertiv (VRT) which he believes is set up for a hull reversion entry. Kevin Green looks at the bullish and bearish technical patterns on each of the stock charts.======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Don Nesbitt is looking for “quality stocks with good earnings.” He sees strength right now in Honeywell (HON), AbbVie (ABBV), and T-Mobile (TMUS). He warns that the top ten companies have to see decent earnings growth to keep markets up, but the other 490 also need to perform well to create market breadth. He considers the market to be in “late cycle expansion.”======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

12 Articles With Great ESG Stock Picks. Includes the terrific Humankind ranking, top infrastructure, lithium mining, and AI stock picks. By Ron Robins, MBA Transcript & Links, Episode 157, July 25, 2025 Hello, Ron Robins here. Welcome to my podcast episode 157, published on July 25, 2025, titled “12 Articles With Great ESG Stock Picks.” Before I begin, I want to let you know that my next podcast will be on August 22nd as I'm taking some time off. So, this podcast is presented by Investing for the Soul. Investingforthesoul.com is your go-to site for vital global, ethical, and sustainable investing mentoring, news, commentary, information, and resources. Remember that you can find a full transcript and links to content, including stock symbols and bonus material, on this episode's podcast page at investingforthesoul.com/podcasts. Also, a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, and I don't receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal any investments I have in the investments mentioned herein. Additionally, please visit this podcast's webpage for links to the articles and additional company and stock information. I have a great crop of 12 articles for you in this podcast! Note that some companies are mentioned more than once! ------------------------------------------------------------- Humankind 100 rankings I'm beginning this episode with another of my favourite company rankings whose annual list has just been released. It's the Humankind 100 rankings. Here is an overview of them from their website. “The Humankind 100 celebrates the one hundred U.S. public companies with the highest Humankind Values. We believe these companies consistently work to create large amounts of value, not just for their investors, but for humanity at large. The Humankind 100 companies are ranked based on Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large, and are therefore among the most ethical companies in the United States, according to our research.” End quotes. Their top 5 companies are Alphabet Inc. (GOOGL), Eli Lilly & Company (1LLY.MI), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), and Pfizer Inc. (PFE). ------------------------------------------------------------- Infrastructure Stocks To Consider - July 12th This second article features a sector favoured by many ethical and sustainable investors. The article is titled Infrastructure Stocks To Consider - July 12th. It's by MarketBeat and seen on marketbeat.com. Here are some quotes from the article. “1. NVIDIA Corporation (NASDAQ:NVDA) provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. 2. Coinbase Global, Inc. (NASDAQ:COIN) provides financial infrastructure and technology for the crypto economy in the United States and internationally. The company offers the primary financial account in the crypto economy for consumers; and a marketplace with a pool of liquidity for transacting in crypto assets for institutions. Read Our Latest Research Report on COIN 3. Alphabet (NASDAQ:GOOGL) offers various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment provides products and services, including ads, Android, Chrome, devices, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube. Read Our Latest Research Report on GOOGL 4. Broadcom (NASDAQ:AVGO) designs, develops, and supplies various semiconductor devices with a focus on complex digital and mixed signal complementary metal oxide semiconductor based devices and analog III-V based products worldwide. Read Our Latest Research Report on AVGO 5. Oracle (ORCL) offers products and services that address enterprise information technology environments worldwide. Its Oracle cloud software as a service offering include various cloud software applications, including Oracle Fusion cloud enterprise resource planning (ERP), Oracle Fusion cloud enterprise performance management, Oracle Fusion cloud supply chain and manufacturing management, Oracle Fusion cloud human capital management, Oracle Cerner healthcare, Oracle Advertising, and NetSuite applications suite, as well as Oracle Fusion Sales, Service, and Marketing.” End quotes. ------------------------------------------------------------- Best Lithium Mining Stocks 2025: Buy Top Mining Stocks Now Every investor knows that lithium is a basic mineral for electric batteries. So, this next article will interest many investors. It's titled Best Lithium Mining Stocks 2025: Buy Top Mining Stocks Now. It's by Farmonaut and found on farmonaut.com. Here are some quotes by Farmonaut on each of their picks. “1. Albemarle Corporation (NYSE: ALB) headquartered in the USA, is the world's largest lithium producer… With operations spanning North America, South America, and Australia, Albemarle boasts: Diversified extraction & processing operations, including high-margin lithium brine and hard rock mining projects Ongoing investments to expand production capacity in Nevada (USA), Chile, and Australia A resilient supply chain and ability to scale output to meet global demand Strategic partnerships with leading EV battery makers Strong commitment to sustainable mining and ESG practices Albemarle's scale, geographic diversification, and innovation position it as one of the best performing mining stocks of 2025. 2. Sociedad Química y Minera de Chile (or SQM) (NYSE: SQM) is South America's lithium market leader. Based in Santiago, Chile, SQM boasts some of the world's largest and lowest-cost lithium brine operations situated in the renowned Lithium Triangle (Chile, Argentina, Bolivia): Extensive lithium reserves & robust extraction technology, delivering high efficiency Geopolitical stability—Chile enjoys a relatively favorable mining regulatory environment compared to other regions Cost-effective production enables SQM to remain highly profitable even as competition heats up Continuous expansion to satisfy increasing global lithium demand for EV batteries and storage solutions Environmental sustainability programs, making SQM attractive for ESG-focused investors SQM competitive positioning ensures it remains a top choice in the best lithium mining stocks to buy for 2025. 3. Livent Corporation (NYSE: LTHM) distinguishes itself by focusing on high-purity lithium chemicals for next-generation battery technologies. With operations in the United States, Argentina, and China, Livent stands out for: Supplying premium lithium hydroxide and carbonate solutions for advanced battery manufacturers Strong partnerships with key players in the EV battery chain, including Tesla Expansion projects in Argentina and the U.S., boosting 2025 production capacity and flexibility ESG and sustainability initiatives for responsible lithium extraction Livent is uniquely positioned for specialty market growth, making it one of the best lithium mining stocks for investors eyeing niche applications and supply chain integration. 4. Piedmont Lithium (NASDAQ: PLL) though a smaller player, it has become a rising star by focusing on high-quality spodumene reserves in the United States—especially in North Carolina's Carolina Tin-Spodumene Belt. Piedmont brings: Strategic U.S. supply source—critical for domestic battery manufacturers and government-led supply chain diversification Fast-tracked expansion projects supported by U.S. regulatory incentives and EV adoption targets Potential to benefit from blockchain-based traceability in mining—enhancing transparency for institutional investors Growing interest from global automakers and battery companies seeking secure lithium supply Piedmont's agility and domestic positioning could mean outsized growth as U.S. policy emphasizes onshoring critical battery mineral chains.” End quotes. ------------------------------------------------------------- 5 Artificial Intelligence (AI) Infrastructure Stocks Powering the Next Wave of Innovations Now, like most investors, you probably are invested in AI stocks, either directly or via funds. Hence, this next article 5 Artificial Intelligence (AI) Infrastructure Stocks Powering the Next Wave of Innovations, should interest you. It's by Justin Pope and found on fool.com. Here is some of what Mr. Pope says about his picks. “1. Nvidia (NASDAQ: NVDA) The company has maintained its winning position as it progressed from its previous Hopper architecture to its current Blackwell chips, and it expects to launch its next-generation architecture, with a CPU called Vera and a GPU called Rubin, next year. Analysts expect Nvidia's revenue to grow to $200 billion this year and $251 billion in 2026.  2. Amazon (AMZN) Web Services (AWS) has long been the world's leading cloud platform, with about 30% of the cloud infrastructure market today. Through the cloud, companies can access and deploy AI agents, models, and other software throughout their businesses. 3. Microsoft (MSFT) Its Azure is the world's second-largest cloud platform, with a market share of approximately 21%. Microsoft stands out from the pack for its deep ties with millions of corporate clients. 4. Arista Networks (ANET) sells high-end networking switches and software that help accomplish this. The company has already thrived in this golden age of data centers, with top clients including Microsoft and Meta Platforms, which happen to also be among the highest spenders on AI infrastructure. 5. Broadcom (AVGO) which specializes in designing semiconductors used for networking applications. For example, Arista Networks utilizes Broadcom's Tomahawk and Jericho silicon in the networking switches it builds for data centers. Broadcom's AI-related semiconductor sales increased by 46% year-over-year in the second quarter.” End quotes. ------------------------------------------------------------- Ethical Companies To Invest In 2025 (ECL, MSFT, UNFI) The final reviewed article for this podcast episode is titled Ethical Companies To Invest In 2025 (ECL, MSFT, UNFI) and was written by the Analyst Team and seen on asktraders.com. Now a few quotes from the article by the Team. “1. Ecolab (ECL) a global leader in water, hygiene, and infection prevention solutions, presents a straightforward ethical narrative. Its products and services help businesses reduce water consumption, improve hygiene standards, and prevent infections, contributing directly to public health and environmental protection… Analyst ratings remain in line with current pricing, with Wells Fargo & Company reiterating a price target of $260.00 in May 2025. With the Ecolab stock price having gained 14% since the start of the year, the company has managed to outperform the market on the period whilst holding true to it's ethical standing. While its dividend yield of approximately 1.1% is slightly higher than others on the list, its P/E ratio of around 38x indicates a similar valuation based on future earnings potential. 2. Microsoft (MSFT) presents a complex ethical profile. On one hand, its commitment to carbon neutrality, investments in renewable energy, and initiatives to bridge the digital divide are commendable… The stock's impressive 20% YTD return and a consensus analyst price target of $475 reflect market confidence in its financial stability and future growth, primarily driven by its cloud and AI segments, making it one to keep on shortlists… While Microsoft offers a modest dividend yield of around 0.7%, its high P/E ratio of approximately 36x suggests a premium valuation reflecting its growth potential rather than a focus on immediate shareholder returns. The company's low debt-to-equity ratio underscores its financial strength, allowing it to invest heavily in research and development and pursue ambitious sustainability goals. 3. United Natural Foods (UNFI) stock has pulled back ~15% this year, although remains firmly higher over the past 12 months, with a gain of more than 70%. The company, a leading distributor of natural, organic, and specialty foods, presents the most challenging investment case with the recent cyber incident causing a sharp pullback in the stock. This could in fact be an opportunity… Unlike Microsoft and Ecolab, United Natural Foods does not offer a dividend, reflecting its current financial constraints. Its low P/E ratio of around 8x suggests a deeply discounted valuation, reflecting the market's skepticism about its turnaround prospects. Recent earnings on July 16 beat expectations, however, and the stock is on the move with an 8% gain immediately off the back.” End quotes. ------------------------------------------------------------- More articles of interest from around the world for ethical and sustainable investors 1. Title: Top 10: Wind Power Companies on energydigital.com. By Jasmin Jessen. 2. Title: Ethical Companies To Invest In 2025 (ECL, MSFT, UNFI) on AskTraders.com. By Analyst Team. 3. Title: The Green Gold Rush: Why Techem's $6.7B Sale Signals a Buying Opportunity on ainvest.com. By Wesley Park. 4. Title: AJ Bell adds Rathbone Ethical Bond to buy list on portfolio-advisor.com. By Christian Mayes. 5. Title: Procter & Gamble Named Top Socially Responsible Dividend Stock on ainvest.com. By Ainvest. 6. Title: 11 Best Halal Dividend Stocks to Buy Now on insidermonkey.com. By Vardah Gill. 7. Title: JPMorgan Picks 3 Top Stocks In Alternative Energy On Heels Of Trump's 'Big Beautiful Bill' - First Solar (NASDAQ:FSLR), Brookfield Renewable (NYSE:BEPC), and HASI (NYSE:HASI) on benzinga.com. By Priya Nigam. ------------------------------------------------------------- Ending Comment These are my top news stories with their stock and fund tips for this podcast, “12 Articles With Great ESG Stock Picks.” Please click the like and subscribe buttons wherever you download or listen to this podcast. That helps bring these podcasts to others like you. And please click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope and prosperity in these deeply troubled times! Contact me if you have any questions. Thank you for listening. As I mentioned earlier, I'm taking some time off, so I'll talk to you next on August 22nd. Bye for now.   © 2025 Ron Robins, Investing for the Soul

In this episode of Dividend Talk, we dive into the drama at UnitedHealth Group (UNH) from earnings disappointments to fraud allegations and a sudden CEO exit. Is it a buying opportunity or a classic falling knife?We also break down strong earnings from two European giants: Siemens (SIE.DE) and Allianz (ALV.DE). Both companies delivered rock-solid results, reminding us why Europe is a fertile ground for dividend growth investors.Along the way, we reflect on what we'd do differently if we started our investing journeys today, why conviction matters more than share price, and whether preferred stocks or spin-offs like Magnum are worth a look.

David Kaplan says AbbVie (ABBV) shows "unusually strong growth compared to peers." While he notes parts of its business is exposed to tariffs, the pharmaceutical and medical device industries are typically resilient to macro headwinds, and he believes AbbVie can withstand most. George Tsilis later joins to offer example options trades in AbbVie and UnitedHealth (UNH).======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

"We currently advise gradually shifting exposure away from high-growth areas toward more value and defensive sectors," notes David Darst. He discusses finding opportunities in an uncertain market. He highlights that emphasis is placed on high-quality companies with strong balance sheets. He then goes over his stock picks: Barrick Gold (GOLD), Estee Lauder (EL), and AbbVie (ABBV).======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Think every stock is selling off right now on tariff fears? Zacks Stock Strategist, Tracey Ryniec, shares a group of stocks bucking the trend.  (0:30) - Finding Strong Stocks Amid A Stock Market Sell-Off (5:00) - Top Stock Picks To Keep On Your Watchlist Right Now (23:10) - Episode Roundup: BRKB, AON, ABBV

A fresh IPO, outgoing CEO, and Domino's finally joining the field on stuffed-crust pizza. (00:21) Bill Barker and Dylan Lewis discuss: - Mixue's splashy debut on the Hong Kong stock exchange, and how the boba tea chain stacks up to Starbucks and McDonald's. - Rodney McMullen's departure from Kroger and what's next for the nation's largest grocery chain. - Domino's finally delivering what the people want: stuffed crust pizza. (17:41) Have you seen a med spa in your neighborhood? Mary Long caught up with analyst Nick Sciple to find out why this industry is booming and one company that's selling a few products that can help you look a little younger. Article discussed: https://www.bloomberg.com/news/articles/2025-02-19/med-spas-boom-with-botox-lip-filler-weight-loss-drugs-in-demand Companies discussed: LKNCY, KR, DPZ, PZZA, ABBV, EOLS Host: Dylan Lewis Guests: Bill Barker, Nick Sciple, Mary Long Producer: Mary Long Engineers: Dan Boyd Learn more about your ad choices. Visit megaphone.fm/adchoices

En este episodio, desglosamos los eventos más relevantes que están impactando los mercados y la tecnología: Mercados atentos a aranceles y datos económicos: El $SPX, Nasdaq 100 y Dow operan estables mientras los inversionistas siguen la incertidumbre sobre los aranceles de Trump a México y Canadá. Además, analizamos el impacto de los próximos datos del PMI e ISM Manufacturing. Bitcoin se dispara por respaldo de Trump: $BTC-USD supera los $95K tras el anuncio de la Crypto Strategic Reserve y la primera Crypto Summit en la Casa Blanca. Evaluamos cómo esto afecta al mercado cripto y qué esperar en el sector. Boston Scientific adquiere SoniVie: $BSX pagará hasta $540M por una nueva terapia de hipertensión. Analizamos cómo esta compra refuerza su portafolio y qué impacto tendrá en su crecimiento. Honor apuesta por la IA: La compañía china invertirá más de $10B en IA en los próximos cinco años, presentando su estrategia en el MWC de Barcelona. Discutimos cómo esto posiciona a Honor en la competencia global de inteligencia artificial. AbbVie entra en el mercado de la obesidad: $ABBV firma un acuerdo con Gubra por hasta $2.2B para desarrollar un tratamiento experimental contra la obesidad. Evaluamos el impacto de esta inversión en el creciente sector farmacéutico. Acompáñanos para analizar cómo estos eventos están transformando los mercados financieros, la tecnología y la biotecnología. ¡Un episodio cargado de información clave!

Today's Big 3 focuses on companies that couldn't be more different, but Prosper Trading Academy's Mike Shorr points to one thing they have in common: choppy price action. He talks about the trends he's watching in AbbVie (ABBV), Electronic Arts (EA), and Constellation Energy (CEG). Rick Ducat turns to the technicals behind all three companies and points out the areas investors should watch.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Motley Fool Senior Analysts Matt Argersinger and Anthony Schiavone join Mary Long to discuss:  - How a company enters into the Dividend Seven. - If Home Depot can still be a growth stock. - The metrics that dividend investors need to understand.  - Companies that have raised their dividend for decades. Companies discussed: PLD, JPM, PEP, HD, ABBV, MCD, BLK Host: Mary Long Guests: Matt Argersinger, Anthony Schiavone Producer: Ricky Mulvey  Engineers: Desireé Jones, Rick Engdahl Learn more about your ad choices. Visit megaphone.fm/adchoices

What Abbreviation Do You Use The Most? | The Autumn Wind = Football | Most Common Bday & Mr. Greedy Has Died | DUGY Lines | OttaWHAT? | Helpful Tips For Our Government Friends Going Back To Work | The 7-10 | Invisible Doritos & Nose Lego | DUGY Lady Goes For Jason's Jugular 

Top Food and Healthcare stocks. And more… Includes a 100-company ranking of companies producing the most favorable human life impacts. By Ron Robins, MBA Transcript & Links, Episode 136, August 23, 2024 Hello, Ron Robins here. It's good to be back after my summer break! So, welcome to this podcast episode 136 titled “Top Food and Healthcare stocks. And more…” Presented by Investing for the Soul. Investingforthesoul.com is your site for vital global ethical and sustainable investing mentoring, news, commentary, information, and resources. Now, remember that you can find a full transcript, and links to content – including stock symbols and bonus material – on this episode's podcast page at investingforthesoul.com/podcasts. Also, a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, and I don't receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal to you any personal investments I have in the investments mentioned herein. Additionally, quotes about individual companies are brief. Please go to this podcast's webpage for links to the articles for more company and stock information. ------------------------------------------------------------- 3 Plant-Based Food Stocks That Could Be Multibaggers in the Making: July Edition I'm starting with this article on food stocks as it's a segment that many of you are interested in. It's titled 3 Plant-Based Food Stocks That Could Be Multibaggers in the Making: July Edition. It's by Philippa Main and found on investorplace.com. Now some quotes from the article. “Investors have many reasons for investing in plant-based food stocks… But there are also a lot of ups and downs in the vegan-friendly and plant-based industries. Even one of the most recognizable names in the vegan meat industry, Beyond Meat (NASDAQ:BYND), has been down consistently over the last five years, with very few times of sustained value. However, the overall sector's potential for growth remains robust… The plant-based food market value is currently at $46.7 billion and could expand to $96.6 billion by 2033. That's a compound annual growth rate (CAGR) of 8.4%... 1. Laird Superfood (NYSEAMERICAN:LSF) Specializes in providing plant-based coffee creamers, hydration supplements and other foods. The stock topped out at $57 in 2020 but has since dropped dramatically. It is now trading at around $4 a share. However, recent quarterly results prove that the company is back on the upswing…  The company's 22% net sales growth during the first quarter was among the top results for any company in the food industry. The company saw at least a 40% gross margin. While the company still operates at a net loss, its balance sheet remains strong with no debt. The company raised its outlook for net sales thanks to the positive Q1 results. Laird Superfood stock is affordable for investors looking to enter the vegan-friendly and plant-based food stocks segment. Laird Superfood has many potential growth opportunities on the horizon… It recently received a $32 million influx of funding from WeWork. All this combined means investing now could see great returns in the long term. 2. SunOpta (NASDAQ:STKL) has been producing plant-based food and beverages for over 50 years. In the past three years, the company has committed over $200 million to expanding production capacity and reaching its goal of doubling its plant-based business by 2025. Across the several segments the company operates in, there is a $22 billion addressable market. The company's nutritional beverages sector saw the largest year-over-year (YOY) growth at 20%. The company also partners with other major names in the food retail industry. These include Costco (NASDAQ:COST), Walmart (NYSE:WMT) and Target (NYSE:TGT). Partnering with big retail brands helps increase the exposure of its products and, in turn, generates higher sales volume. SunOpta stock has had its ups and downs over the past five years but currently has a 93% upside. 3. Tyson Foods (NYSE:TSN) One of the most well-known chicken brands in the U.S. may not seem like a good pick for a list of plant-based food stocks. For investors who want to feel good about investing in companies working toward making more plant-based options but don't want to gamble on a company solely focused on that sector, Tyson Foods is a good way to diversify.  Though down substantially over the last five years, Tyson Foods stock has seen a rally of 10% in the last 12 months and 6.5% year-to-date (YTD). In the previous five years, Tyson has been increasing its plant-based offerings through its brand, Raised and Rooted, and has 10 plant-based products. These include plant-based patties, ground meat substitutes, sausages and nuggets. As inflation dampens demand for meat as prices soar, Tyson's presence in the plant-based industry will give it a head start compared to its competitors.  Though there have been some financial troubles for the company in the last year or so, things are starting to turn around.” End quotes. ------------------------------------------------------------- The energy transition from fossil fuels will power these stocks - including Big Oil Now, this next article acknowledges the energy transition, however, some of the comments and companies suggested will not appeal to many ethical and sustainable investors. I wondered long and hard as to include this article or not. However, since the European Commission is likely to include natural gas in its preferred funding energy financing initiative, I ‘dared' to include it. The article is titled The energy transition from fossil fuels will power these stocks - including Big Oil. It's by Jakob Wilhelmus, provided by Dow Jones, and found on morningstar.com. Here are some quotes. “Modernizing the grid The International Energy Agency estimates that to power itself primarily with renewable energy, the world would need to add or replace nearly 50 million miles of transmission lines by 2040… For investors, that creates opportunity around the complementary infrastructure that is needed to build out the grid. Companies such as Eaton (ETN) that provide essential components - including inverters or substations for transmission lines - are well-positioned to take advantage of these ambitious goals. Their central role in the energy transition over coming years may not be fully appreciated today, but markets might soon catch up. Shifting to the greener end of fossil fuels Fossil fuels will certainly continue to be a component of the energy system of the future…  Indeed, global demand for liquified natural gas (LNG) is expected to grow by more than 50% by 2040 as the coal-to-gas transition expands in China and South Asia… For investors, it is critical to seek energy-sector companies that are forward-looking and are finding ways to remain energy providers regardless of what the primary energy sources might be. Two such companies are TotalEnergies (TTE) and Shell (SHEL), which are expanding natural-gas production and transport capabilities. Pipelines are another way to take advantage of the global shift to natural gas. Often these firms have long-term purchase agreements in place, providing investors with an attractive ‘toll collection' that provides a differentiated risk-return proposition in the natural-gas space: exposure to booming demand with less exposure to short-term price volatility. These characteristics and accompanying cash flows make major pipeline players including Enbridge (ENB) and Kinder Morgan (KMI) particularly interesting for debt investors. Getting smart on energy use Investors should also pay close attention to innovation around managing demand and using energy supplies more efficiently… This has created a two-way system, where customers actively manage their energy consumption through smart appliances or storage, while system operators have increased capabilities to manage electricity distribution and generation. This development might benefit companies, such as Schneider Electric (SBGSY), that provide smart sensors and devices all the way to the software that allows grid operators to optimize supply and demand… Global renewable capacity grew by 50% in 2023 and these sources offer some of the lowest cost of producing electricity today. But even this pace of growth in renewables may not be enough to account for the steep rise in energy demand.” End quotes. ------------------------------------------------------------- The 3 Best Healthcare Stocks to Buy in August 2024 Now, here's an article on another favorite sector, healthcare, and it's titled The 3 Best Healthcare Stocks to Buy in August 2024. It's by investorplace.com and was seen on markets.businessinsider.com. Here are some interesting quotes. “The healthcare industry has been a critical part of the economy for a long time. According to a McKinsey & Company report, the healthcare industry is expected to grow at 7% from 2022 to 2027. 1. Bristol-Myers Squibb (NYSE:BMY). The pharmaceutical powerhouse consistently ranks as one of the top companies on the market, and has several drugs that generate billions of dollars in revenue. Furthermore, Bristol-Myers Squibb has a number of drugs currently in clinical trials that could bring in huge success over the next decade. Among these is schizophrenia treatment Eliquis KarXT. The drug is expected to receive a recommendation from the FDA as early as next month. If it gets approved, it will be the first newly developed treatment for schizophrenia. That is a market that is estimated to grow to more than $7 billion in just four years. Right now, the stock is down over 10% this year alone and 20% year-over-year. Investors should buy while the stock is down.  2. AMN Healthcare Services (NYSE:AMN) is a medical care facilities company. It supplies healthcare workers, including nurses and industry professionals, on a temporary basis. It experienced huge success from high healthcare worker demand when there was a worker shortage. For those investors who are looking for high-risk, high-reward healthcare stocks, AMN should be on their radar. The company's recent earnings reports look very promising. In Q2 2024, AMN reported earnings per share (EPS) of 98 cents, beating analyst's estimates by almost 20 cents. This was the fourth consecutive quarter that AMN Healthcare Services beat the earnings estimate. Furthermore, AMN trades at 13.64 times forward price to earnings ratio, which is lower than the majority of its competitors in the market. Before it bounces back to its peak price from 2022, investors should buy the stock. 3. Rapport Therapeutics (NASDAQ:RAPP), a biotech company that is backed by Johnson & Johnson (NYSE:JNJ). The company went public on June 7th of this year, and it raised $154 million in initial public offering. The stock price ended up to over $20 on the first day it went public, and as of writing, it goes for $19.05. While there is still lots to learn about the company as it is new to the market, there are certainly things that will attract many investors.  Rapport Therapists is currently developing a focal epilepsy drug. The phase two trials should begin in the next few months, which means that there is going to be exciting news for the biotech startup for the upcoming years. This is especially exciting considering that in the U.S. alone, there are more than three million adult epilepsy patients, which means that it is a sizable market with room to explore.” End quotes. ------------------------------------------------------------- The 2024 Humankind 100 List This next article is a company ranking I watch every year as its methodology is fascinating. It's the Humankind 100 List and the 2024 edition has just been published. I found it on businesswire.com. Here are some quotes. “As the challenges of creating transparency around Environmental, Social and Governance (ESG) data and rankings become increasingly apparent, Humankind developed a holistic, quantitative way to calculate impact in terms of human benefit versus human suffering… This year, Alphabet (GOOGL)… scored highest in the ranking. The positive value of creating free digital tools for consumers outweighs the negative impact of factors like data harvesting in Humankind's analysis. Other companies rounding out the top 10 include: Eli Lilly & Co. (LLY), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), Merck & Co. (MRK), Procter & Gamble (PG), Pfizer (PFE), Amgen (AMGN), Microsoft Corp (MSFT), and Bristol-Myers Squibb (BMY). The complete rankings… can be found at rankings.humankind.co.” End quotes. ------------------------------------------------------------- Finally, here's one other article that will interest some of you. It's titled Bank of New York Mellon a Top Socially Responsible Dividend Stock With 2.9% Yield. It's by BNK Invest and found on Nasdaq.com. ------------------------------------------------------------- Ending Comment Well, these are my top news stories with their stock and fund tips for this podcast titled: “Top Food and Healthcare stocks. And more…” Please click the like and subscribe buttons on Apple Podcasts, Google Podcasts, or wherever you download or listen to this podcast. That helps bring these podcasts to others like you. And please click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope and prosperity in these troubled times! Contact me if you have any questions. Thank you for listening. Now my next podcast will be September 6th. I'll talk to you then! Bye for now.   © 2023 Ron Robins, Investing for the Soul  

Dr. Shaalan Beg and Dr.Mohamed Salem discuss key abstracts that will be presented at the 2024 ASCO Annual Meeting, including hypoxia-response CAR T- cell therapy for solid tumors, GPC3-specific CAR T- cell therapy in hepatocellular carcinoma, and the promising efficacy of targeted therapies in GI cancers.  TRANSCRIPT Dr. Shaalan Beg: Hello and welcome to the ASCO Daily News Podcast. I am Dr. Shaalan Beg, your guest host of the podcast today. I'm an adjunct associate professor at UT Southwestern's Simmons Comprehensive Cancer Center. In today's episode, we'll be discussing some key abstracts in GI cancers that will be presented at the 2024 ASCO Annual Meeting. I'm delighted to welcome Dr. Mohammed Salem, a GI medical oncologist at the Levine Cancer Institute at Atrium Health, for this discussion. Our full disclosures are available in the transcript of this episode. Mohammed, it's great to have you back on the podcast. Dr. Mohamed Salem: Thank you, Dr. Beg. It's always a pleasure to be here. Thanks for having me.  Dr. Shaalan Beg: So we're seeing more and more exciting data emerge on the role of ctDNA in GI cancers. And that's a topic that we've covered fairly extensively on the podcast. This year, in Abstract 3513, investigators used a novel, highly sensitive HPV ctDNA assay to evaluate the clinical outcomes of HPV ctDNA status in people with localized anal cancer treated with chemoradiation. And we know that prior HPV infection is associated with 90% of anal cancers. Can you give us a summary of the study and why it's so important to the clinical care we're giving our patients today?  Dr. Mohamed Salem: Sure. So, as you already alluded to, in the current era of precision oncology or precision medicine in general, there is an effort to try to maximize treatment efficacy and minimize the side effects. We're trying to understand how to do that by developing more biomarkers. I think this was a very interesting study that was led by Dr. Morris of MD Anderson. As you mentioned, he tried to determine the correlation between that circulating tumor DNA at different timelines and also associated that with the relapse. Obviously, as we all know, HPV infection is linked to about over 90% of anal cancers, and anal cancer is increasingly common in the U.S.  The study design includes patients from stage 1, 2, and 3 anal cancer treated with curative intent concurrent chemo radiation and the plot sample to collect circulating DNA was taken at five weeks of treatment and then at various intervals, including 3months, 6  months, 9 months and 12 months, to detect the HPV circulating DNA. And the analysis was done to correlate detection of circulating DNA with a relapse.  So what they observed is after collecting the samples at the end of the treatment, which is 5 weeks, followed by 3 months, 6 months, 9 months, and 12 months following treatment using the correlation between the detection of circulating tumor DNA as well as the recurrence rate, they were able to identify that about 22% was seen at 5 weeks, 13% was seen at three months, then 10% was seen at 6 months, and 0% actually was seen at 12 months. In the final analysis, they concluded that detection of circulating DNA at 3 months was significantly associated with a relapse rate of those patients. And also, they looked at the baseline stage, T stage, end stage, age and other perhaps prognostic factors. But the clinical implication of that trial is this finding supports the potential of integrating now the circulating DNA analysis and routine post-treatment surveillance, which hopefully will help us identify those patients with high risk of relapse and whether they can be treated with adjuvant therapy  in context-free drug trial or even like more close surveillance. Obviously, this is a very novel study, so it needs validation. Also, we need to understand more about the platform used because with the immersion technology and how fast this field is moving, I think it's important to look at this platform or other platforms. I think as a concept it's very interesting and hopefully will help us to identify patients with higher risk. So, I'm looking forward to hearing the full presentation. Dr. Shaalan Beg: Moving on to colorectal cancer, Abstract 3514 is a trial of hypoxia-responsive CEA CAR T-cell therapy for people with heavily pretreated solid tumors where this was administered intraperitoneally or intravenously. And you know, as a solid tumor oncologist or GI oncologist, we've been watching the hematologic space evolve so dramatically in the last five years with cellular therapies that it's exciting to see these CAR T-cell approaches being applied in solid tumors with some results. So can you talk about this study and whether you think it will influence clinical practice?  Dr. Mohamed Salem: Of course, I'm actually very excited to see this study because as you mentioned, CAR T-cell therapy has been utilized in hematological malignancies for the last several years and in fact it's becoming a center of care. As you know, it's very effective in certain tumors. Unfortunately, we did not see a similar result in solid tumors thus far. I know we are trying to make progress, but we are definitely not seeing the same efficacy in solid tumors. And also, of course, in CRC and many other tumors, we need more target options, so I was very excited to see this abstract. And I want to give a little bit of background why this abstract is important. Many solid tumors have a low oxygen level environment, hypoxia obviously, which can impact the effectiveness of CAR T therapy. So hypoxia can suppress the immune response, leading to poor performance of the immune cells like the T cell within the tumor. The investigators, to overcome that challenge, meaning hypoxia impacting the efficacy of the T cell, they were actually able to engineer a CAR T cell to be hypoxia responsive. And what does that mean? That the cells are designed to become more active in low oxygen conditions, which is more difficult in many of the solid tumors. The reason that's very interesting is because, one, it reduces exhaustion of the T cell, meaning like when you have the T cell active all the time, they get exhausted. So when you have the T cell in the resting state, until they reach the tumor environment and they get activated by the hypoxia status, now you reduce the expulsion of the T cell. But also that one overcomes the resistance. So once activated in the tumor hypoxic environment, this CAR T cell shows increased efficacy in targeting and killing the cancer cell.  Based on that concept, the investigators conducted a phase 1 dose escalation study in solid tumors. So this was a phase 1 open label group escalation study involving patients with tumor suppressed CEA and also had relapsed refractory second line treatment. The trial actually included 2 routes of administration, which I think was very interesting – IV versus intraperitoneal, IP, way of administration. And they enrolled about 40 patients between June of 2022 and January 2023. And 35 patients had colorectal cancer, 3 patients had gastric cancer, and 2 patients had non-small cell lung cancer. Overall, there was no surprising safety data. In terms of side effects, it was largely macrocystis, colitis. Unfortunately, they had 1 treatment that did not finish. But the interesting feature was the efficacy of that concept was demonstrated and in fact they were able to see more disease response and control at this rate with IP infusion, which I think is a very novel approach. I would look forward to trying and looking into this kind of delivery, especially in CRC and other tumors. Dr. Shaalan Beg: Because we've known that historically managing disease intraperitoneally has been challenging with cytotoxic chemotherapies and even surgical approaches that have been deployed can be fairly morbid as well. So looking at novel delivery mechanisms can help us understand, maybe be able to manage side effects of treatments in different ways and open doors for treatment in diseases that otherwise we couldn't manage. So definitely a very novel and exciting approach on this study.  Dr. Mohamed Salem: I agree. I think the idea of administering an IP route is a very interesting idea.   Well, Shaalan, there is another study in CRC, Abstract 3515. This is the first human study of ABBV-400, cMET–targeting antibody-drug conjugate in advanced solid tumors. Can you tell us about this promising data? Dr. Shaalan Beg: Yeah, so we've known that cMET is a very relevant biomarker across many cancers, particularly colorectal cancer, and it is overexpressed in a fairly large proportion of multiple diseases. But there hasn't been an effective regimen that has been found to be tolerable to target this specific biomarker. In this study, the investigators are evaluating an antibody drug conjugate, which takes the cMET targeting antibody telisotuzumab and conjugates it to a novel topoisomerase one inhibitor payload. And there's a phase one study that enrolled people across multiple different tumor types. This was presented at ASCO 2023. And this year, the investigators are coming in and giving the results of a colorectal cancer cohort within that study. Patients were enrolled in the dose escalation phase, and in the dose expansion phase, there were 122 colorectal cancer cases; so a fairly healthy size colorectal cancer population. And the median number of prior lines of therapy was 4, which is fairly consistent with what we would expect in our clinical population for people with colorectal cancer. So what they found in terms of efficacy is that the response rates, the confirmed overall response rates, were between 15 and 20%, depending on what dose of the medication the patients had received. They enrolled people regardless of cMET expression and then evaluated the response based on a higher or lower cMET expression. And those with higher cMET expression had an overall response rate of >30%, while those with lower cMET expression had a response rate of 10 to 15%. So they still had a response rate, which for fifth-line colorectal cancer is something to be aware of and it could be a marker of more significant clinical activity than other treatments that are out there.  And with the antibody drug conjugates, it's also important for us to keep an eye on the side effect profiles because a lot of these agents can have distinct side effect profiles that otherwise we wouldn't be familiar with. And in this study, 64% of participants had a grade 3 or above treatment emergent adverse events, and 41% had serious adverse events. So definitely something to think about. And most of these were hematologic toxicities, 30% had grade 3 or worse anemia. Neutropenia was seen, in grade three and above, was seen in 25%, leukopenia or grade three and above was seen in 12%, and thrombocytopenia again around 12%. And the non-hematologic toxicities were nausea, fatigue, vomiting and diarrhea. There was some interstitial lung disease, pneumonitis, which was seen in 7% of the total population, of which 2% had grade three or above. So definitely something to think about. From my perspective, I really am excited about this presentation because we're seeing evidence of clinical activity focused on cMET for refractory colorectal cancer compared to other agents that are out in the market. If this pans out in future studies, it could definitely change the way we deliver our treatments. Dr. Mohamed Salem: I totally agree that we actually need more therapy for those patients. And I'm not surprised that the myelosuppression, as you mentioned, was in fifth-line treatment. So this patient had large exposure to cytotoxic agents before.   So, looking at CAR T once more, there is a very interesting Abstract 4019, which is a study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR T, in patients with advanced hepatocellular carcinoma (HCC). What are your key takeaways from this study, Shaalan? Dr. Shaalan Beg: This is a first-in-human study. It enrolled people with advanced HCC who failed on one or more lines of prior therapy and they were given one single infusion of C-CAR031 after standard lymphodepletion and they enrolled 24 patients across 4 dose levels. If we look at the overall response rate, 50% of the 22 people who were eligible for response assessments had a partial response. This response rate varies based on the dose level itself and the investigators claim a 90% disease control rate. So definitely when we think about standard treatments for hepatocellular cancer after first line therapy, this is something which will catch a lot of people's attention. Again, with CAR T-cell therapy, we need to be aware of the risk of potential toxicities. There were no dose limiting toxicities and CRS or cytokine release syndrome was observed in 91% of patients, while a very small proportion, about less than 5%, had grade three CRS. Most of the side effects here were, again, lymphocytopenia, neutropenia, thrombocytopenia, and some transaminitis in 16% of patients. They did see tumor reduction in 90%, not only in the intrahepatic disease, but also in the extrahepatic disease. And again, these are people who had BCLC stage C disease. So this included people with hepatic and extrahepatic metastases. And in terms of prior lines of therapy, 96% of patients had either received immune checkpoint inhibitors and TKIs.  If we think about how some other immune therapy regimens are being developed in the GI cancer space, there is some indication that liver lesions may respond differently compared to extra hepatic disease. So in this case, they saw responses in both scenarios, which makes it very exciting, because even though we've seen many approvals of TKIs and immunotherapy, anti-androgenic therapy in hepatocellular cancer, the treatment of these patients is still extremely difficult because of their underlying hepatic dysfunction. And it'll be very interesting to see how this treatment unfolds.  Dr. Mohamed Salem: You summarized it very well, Shaalan. I echo your thoughts. What is also interesting about that study, it's actually targeted at the GPC strain, which is prevalent in HCC but not normal tissue, which goes back to your comment about the toxicity, and hopefully we can also manage treatment in the context of underlying liver disease.  Dr. Shaalan Beg: I guess it's fair to say that we're both very excited to see what's ahead in GI cancers at the Annual Meeting.   Mohamed, thanks as always for sharing your great insights with us on the ASCO Daily News Podcast.  Dr. Mohamed Salem: Thank you all for having me, and I'm looking forward to meeting you and all our colleagues in Chicago in a couple of weeks. Dr. Shaalan Beg: And thank you to our listeners for your time today. You'll find links to the abstracts discussed today in the transcripts of this episode. I'll be back to cover late breaking abstracts and other key advances in GI oncology after the annual meeting, so please join me for more key insights from ASCO24 and on the ASCO Daily News Podcast. Finally, if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:  Dr. Shaalan Beg  @ShaalanBeg  Dr. Mohamed Salem  @SalemGIOncDoc    Follow ASCO on social media:  @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn   Disclosures: Dr. Shaalan Beg:  Consulting or Advisory Role: Ispen, Cancer Commons, Foundation Medicine, Genmab/Seagen  Speakers' Bureau: Sirtex  Research Funding (An Immediate Family Member): ImmuneSensor Therapeutics  Research Funding (Institution): Bristol-Myers Squibb, Tolero Pharmaceuticals, Delfi Diagnostics, Merck, Merck Serono, AstraZeneca/MedImmune    Dr. Mohamed Salem: Consulting or Advisory Role: Taiho Pharmaceutical, Exelixis, Bristol-Myers Squibb, Exelixis, QED Therapeutics, Novartis, Pfizer, Daiichi Sankyo/Astra Zeneca  Speakers' Bureau: Genentech/Roche, Taiho Pharmaceutical, Daiichi Sankyo/Astra Zeneca, BMS, Merck 

In this video, we'll perform an ABBV stock analysis and figure out what AbbVie looks like based on the numbers. We'll also try to figure out what a reasonable fair intrinsic value is for AbbVie. And answer is AbbVie one of the best stocks to buy at the current price? Find out in the video above! Global Value's AbbVie stock analysis. Thank you for watching. ❤️ Please support the channel by checking out our affiliates. All commissions are reinvested to improve the quality of videos! -

@AviNMash @JoeySolitro @StockSavvyShay are back for Episode 96 after Avo Locks nailed $NFLX buy on last weeks episode (Joey props too for the Buy hat tip)  Underdog Pickem's - 1 minute who we like this week in the NFL  Recap and New Buy | Sell | Hold  Tesla | Align Technology |  TransMedics Group | Netflix  EARNINGS PREVIEW:  Meta | Microsoft | Spotify | Snapchat | Amazon  Monday: $CDNA, $LOGI, $CLF, $WHRTuesday: $KO, $VZ, $GE, $GM, $SPOT, $MSFT, $V, $SNAP, $TXN, $TDOCWednesday: $TMUS, $BA, $ADP, $CZOO, $META, $IBM, $NOW, $ALGN, $MAT, $QS, $PIThursday: $MA, $MRK, $CMCSA, $UPS, $LUV, $MBLY, $OPRA, $AMZN, $INTC, $CMG, $F, $ENPH, $LHX, $DXCMFriday: $XOM, $CVX, $ABBV, $SNY, $CHTR, $TROWCHECK OUT SPECIAL PROMOTIONS FOR OUR LISTENERS: Exclusive UNDERDOG FANTASY SPORTS Get up to Bonus Match instantly (Up to $500) and win up to $3M in their BestBall Mania + $15M In total Prizes.  Promo Code: PTT Signup Link: https://play.underdogfantasy.com/p-pounding-the-table Interested in Automated Trading Bots?  Peakbot is our favorite automated trading bots; great for non experts to leverage covered calls. PeakBot (www.UsePeakBot.com)Promo code: PTTWant to Contact Us?  Email us at Hosts@PoundingTheTablePodcast.comLegal Disclaimer:The thoughts and opinions expressed on this podcast, are solely for entertainment purposes and should not be construed as investment advice. The content provided is based on personal experiences, analysis, and general knowledge about stocks and the financial market.The information shared on this podcast is not intended to be a substitute for professional financial advice. Listeners should always consult with a qualified financial advisor or professional before making any investment decisions. Investing in stocks and other financial instruments carries inherent risks, and individuals should carefully consider their own financial situation, risk tolerance, and investment goals before engaging in any investment activities.The hosts and guests on this podcast are not licensed financial advisors or professionals. They are sharing their personal opinions and experiences, which may not be suitable for everyone. The accuracy, completeness, and timeliness of the information presented cannot be guaranteed, as the stock market and investment landscape are subject to constant changes.Any actions taken based on the content of this podcast are done at the listener's own risk. The podcast hosts, guests, and producers assume no responsibility or liability for any investment decisions, losses, or damages incurred as a result of the information provided on the podcast.

In this video, we'll perform an ABBV stock analysis and figure out what AbbVie looks like based on the numbers. We'll also try to figure out what a reasonable fair intrinsic value is for AbbVie. And answer is AbbVie one of the best stocks to buy at the current price? Find out in the video above! Global Value's AbbVie stock analysis. TIKR is the website I use for all financial data in my videos. Join me and thousands of investors worldwide by using TIKR to supercharge your investment analysis. All funds from referrals directly support the channel to improve video quality! Referral link - https://www.tikr.com/globalvalue Check out Seeking Alpha Premium and score a 14-day free trial. Plus all funds from affiliate referrals go directly towards supporting the channel! Affiliate link - https://www.sahg6dtr.com/H4BHRJ/R74QP/ If you'd like to try Sharesight, please use my referral link to support the channel! https://www.sharesight.com/globalvalue (remember you get 4 months free if you sign up for an annual subscription!) Discover new investing resources and directly support the channel by shopping my Amazon storefront! All commissions are reinvested to improve the quality of videos! https://www.amazon.com/shop/globalvalue AbbVie ($ABBV) | AbbVie Stock Value Analysis | AbbVie Stock Dividend Analysis | ABBV Dividend Analysis | $ABBV Dividend Analysis | AbbVie Fair Value | ABBV Intrinsic Value | ABBV Fair Value | AbbVie Intrinsic Value | AbbVie Discounted Cash Flow Model | AbbVie DCF Analysis | ABBV Discounted Cash Flow Analysis | ABBV DCF Model #ABBV #AbbVie #ABBVstock #AbbViestock #stockmarket #dividend #stocks #investing #valueinvesting #dividendstocks #dividendkings #investor #valueinvestor #stockanalysis #dividend #dividends (Recorded July 8, 2023) ❖ MUSIC ❖ ♪ "Lift" Artist: Andy Hu License: Creative Commons Attribution 3.0 ➢ https://creativecommons.org/licenses/by/3.0/legalcode ➢ https://www.youtube.com/watch?v=sQCuf...

The Sustainable Stocks The Rich Invest In! Includes the following articles: “10 Sustainable Investing Stocks Billionaires Are Loading Up On”; “The 2023 Humankind 100 Rankings”; “4 ESG Stocks With Net-Zero Emissions Target in the Spotlight”; “What is Renewable Energy? Benefits, Sources, and Top Companies”; “'America is going to lead again': Biden says wind and solar are already 'significantly cheaper' than coal and oil — 3 top US clean energy stocks to watch”; and “The Importance Of Sustainable And Impact Investing And 3 Companies That Shine!” Transcript & Links, Episode 111, July 28, 2023 Hello, Ron Robins here. So, welcome to my podcast episode 111 titled “The Sustainable Stocks The Rich Invest In!” It's presented by Investing for the Soul. Investingforthesoul.com is your site for vital global ethical and sustainable investing mentoring, news, commentary, information, and resources. And look at my newly totally revised website at investingforthesoul.com! Tell me what you think. Now, remember that you can find a full transcript, and links to content – including stock symbols and bonus material – on this episode's podcast page located at investingforthesoul.com/podcasts. Also, a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, nor do I receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal to you any personal investments I have in the investments mentioned herein. Additionally, quotes about individual companies are brief. Please go to this podcast's webpage for links to the actual articles for more company and stock information. Also, some companies might be covered more than once and there are also 4 article links below that time didn't allow me to review them here. ------------------------------------------------------------- The Sustainable Stocks The Rich Invest In! I'm beginning with this fascinating article titled 10 Sustainable Investing Stocks Billionaires Are Loading Up On. It's by Ramish Cheema and found on finance.yahoo.com. Here's some of what Mr. Cheema has to say. Note: the number of billionaires quoted is at the end of Q1 2023. Quote. “To compile our list of billionaire sustainable stock picks we first used the Invesco MSCI Sustainable Future ETF (ERTH) and picked out the top forty companies. Then, the number of billionaires that had invested in them as of Q1 2023 was determined and the final list of top ten sustainable stocks according to billionaires is as follows. 10. Ormat Technologies, Inc. (NYSE:ORA) Number of Billionaire Investors: 9 Ormat Technologies is a utility company that focuses primarily on generating power through geothermal sites and solar cells… Out of [24 hedge funds], the firm's largest investor is Ian Simm's Impax Asset Management (IPX.L) with a stake worth $178 million. 9. NextEra Energy Partners, LP (NYSE:NEP) Billionaire Investors: 9 NextEra Energy Partners is an energy company that operates in the natural gas and renewable power industries. The firm announced in May 2023 that it plans to reach Real Zero emissions by 2025 and sell natural gas assets to finance future growth. 8. NIO Inc. (NYSE:NIO) Billionaire Investors: 9 NIO is an electric vehicle manufacturer headquartered in Shanghai, China. It makes and sells both SUVs and sedans and the firm is one of the dominant players in the growing Chinese electric vehicle market. However, a slowdown in the Chinese economy [reduced] vehicle deliveries [by] a sharp 17% annual drop… NIO's largest hedge fund investor [out of 18 hedge funds] is Jim Simons' Renaissance Technologies since it owns ten million shares that are worth $113 million. 7. KB Home (NYSE:KBH) Billionaire Investors: 10 KB Home is an American construction company headquartered in Los Angeles, California. As part of its sustainability push, particularly since construction uses high volumes of timber, the firm announced in July that it will partner up with a nonprofit to fund efforts seeking to preserve landscapes and forest habitats… Among [29 hedge funds], Ken Fisher's Fisher Asset Management is the biggest shareholder with an investment of $110 million. 6. Sunrun Inc. (NASDAQ:RUN) Billionaire Investors: 10 Sunrun is a solar power equipment provider which serves the needs of residential customers in the U.S. by providing products such as panels and energy systems… William B. Gray's Orbis Investment Management is the largest investor [out of 27 hedge funds], courtesy of a $265 million stake that comes via 13 million shares. 5. Meritage Homes Corporation (NYSE:MTH) Billionaire Investors: 10 Meritage Homes Corporation is a construction company that builds different kinds of single family homes in several American states. The firm's shares… are rated Buy on average… The largest [out of 27 hedge funds] is Ken Fisher's Fisher Asset Management with a stake worth $128 million. 4. Darling Ingredients Inc. (NYSE:DAR) Billionaire Investors: 11 Darling Ingredients is a food raw materials firm that focuses its efforts on ensuring that no portion of an animal is wasted during the slaughtering process… [Out of 29 hedge funds] Darling Ingredient's largest investor is Ian Simm's Impax Asset Management since it owns $240 million worth of shares. 3. Enphase Energy, Inc. (NASDAQ:ENPH) Billionaire Investors: 12 Enphase Energy sells solar power products such as microinverters, charging solutions… to residential users… [Out of 55 hedge funds], the biggest shareholder is Jim Simons' Renaissance Technologies through a $198 million investment. 2. First Solar, Inc. (NASDAQ:FSLR) Billionaire Investors: 13 First Solar is an international solar power company that sells products including solar modules to large scale users such as utilities, commercial, and industrial users. Its shares are rated Buy on average… [Out of 39 hedge funds] First Solar's largest investor [is] Jim Simons' Renaissance Technologies with a $312 million stake. 1. Tesla, Inc. (NASDAQ:TSLA) Billionaire Investors: 15 The firm has been facing mixed sentiment from Wall Street in July 2023 after a spectacular stock rally earlier this year. [Out of 82 hedge funds] D. E. Shaw's D E Shaw is the biggest shareholder through its $1.2 billion investment.” End quotes. ------------------------------------------------------------- The 2023 Humankind 100 Rankings The corporate ranking data in this next piece The 2023 Humankind 100 Rankings will be of great interest to most of you. Here's a brief description of what it's about. Quote. “Humankind 100 companies tend to contribute positively to humanity, for example by providing access to food, clean water, healthcare, or free digital services. Meanwhile, companies that hurt people, for example by contributing significantly to climate change or selling toxic products, tend to not make it on to the list.” End quotes. Do have a look at the ranking! The top five companies are Alphabet (GOOG), Microsoft Corp. (MSFT), Eli Lilly & Company (LLY.TI), Johnson & Johnson (JNJ), and Abbvie Inc. (ABBV). ------------------------------------------------------------- 4 ESG Stocks With Net-Zero Emissions Target in the Spotlight Next, we have this article titled 4 ESG Stocks With Net-Zero Emissions Target in the Spotlight. It's by Ritujay Ghosh and found on 247wallst.com. Here's some of what the writer says about their stock picks. “1. Salesforce, Inc. (CRM Quick Quote CRM - Free Report) has successfully attained net-zero residual emissions throughout its value chain. Salesforce has also accomplished its objective of operating solely on 100% renewable energy… Salesforce's expected earnings growth rate for the current year is 42%... Salesforce currently sports a Zacks Rank #1 (Strong Buy). 2. PepsiCo, Inc. (PEP Quick Quote PEP - Free Report) the global beverage giant, is committed to achieving net-zero greenhouse gas emissions by 2040. As part of its sustainability efforts, PepsiCo is actively promoting regenerative agricultural practices… Another key target for PepsiCo is to ensure that all its packaging materials become recyclable, compostable and biodegradable. PepsiCo's expected earnings growth rate for the current year is 9.9%... PepsiCo currently carries a Zacks Rank #2 (Buy). 3. Adobe Inc. (ADBE Quick Quote ADBE - Free Report) aims to attain a zero-carbon operational footprint, emphasizing the development of digital products that have a positive environmental impact. Adobe is actively working toward achieving a 100% renewable energy target by 2035… Adobe's expected earnings growth rate for the current year is 14.5%... Adobe currently sports a Zacks Rank #1. 4. Microsoft Corporation (MSFT Quick Quote MSFT - Free Report) is actively pursuing various initiatives to achieve a net-negative carbon footprint by 2030… Microsoft's expected earnings growth rate for the current year is 4.8%. Shares of Microsoft have gained 23.7% in the past three months. Microsoft currently has a Zacks Rank #3 (Hold).” End quotes. ------------------------------------------------------------- What is Renewable Energy? Benefits, Sources, and Top Companies Now to another new article on renewable energy picks. The article is titled What is Renewable Energy? Benefits, Sources, and Top Companies. It's by Jennifer L. located on carboncredits.com. Now to some quotes from the analyst. “1. General Electric Co. (GE) General Electric has been at the forefront of wind energy technology, consistently enhancing turbine designs and improving efficiency… GE has installed over 49,000 units that generate wind electricity across the globe… GE has also invested in other renewable energy technologies, such as solar power, hydroelectricity, and hybrid. 2. NextEra Energy, Inc. (NEE) Running with a whopping $147 billion market cap, NextEra Energy has been investing billions in developing renewable energy sources. As one of the largest renewable energy producers in the world, the company leads the charge in solar and wind energy production… 3. Iberdrola SA (IBDRY) With a market cap of over $72 billion, Spain-based multinational electric utility company Iberdrola SA has more than 170 years of history. The company is a global leader in the generation, distribution, and trading of clean energy. 4. Orsted A/S (ORSTED.CO) Renewable energy company Orsted A/S excels in developing, building, and operation of offshore wind farms. The Danish firm currently owns the prestigious title of being the world's biggest offshore wind power developer, with a total capacity of over 7.5 GW.” End quotes. ------------------------------------------------------------- 'America is going to lead again': Biden says wind and solar are already 'significantly cheaper' than coal and oil — 3 top US clean energy stocks to watch And more on renewable energy with this article 'America is going to lead again': Biden says wind and solar are already 'significantly cheaper' than coal and oil — 3 top US clean energy stocks to watch. It's by Vishesh Raisinghani on finance.yahoo.com. “1. First Solar (NASDAQ:FSLR) First Solar is one of the nation's largest utility-scale solar energy producers. The company's competitive edge stems from its proprietary, advanced thin-film module technology… Investors seeking a high-growth bet in this sector should add FirstSolar to their watchlist. 2. Brookfield Renewable (NYSE:BEP) If you're looking for a less risky and more established player in the renewable energy sector, Brookfield Renewable might be a wise bet. The Canada-based asset manager operates one of the largest green energy portfolios in the world… Brookfield is a dividend juggernaut. The stock offers a dividend yield around 4.6% at the moment. 3. SolarEdge Technologies (NASDAQ:SEDG) SolarEdge has rapidly become one of the most well-known and valuable solar energy firms on the market. The company offers an end-to-end system that generates, stores and manages solar energy from home. Nearly three million homes across the globe were equipped with SolarEdge systems by the end of 2022.” End quotes. ------------------------------------------------------------- The Importance Of Sustainable And Impact Investing And 3 Companies That Shine! And I finish up with this article titled The Importance Of Sustainable And Impact Investing And 3 Companies That Shine! It's by Finance Monthly and published on finance-monthly.com. Now some quotes on their recommendations. “1. ICL Group (NYSE: ICL) ICL Group is global specialty minerals company and one of the largest fertilizer manufacturers in the world. ICL focuses on creating sustainable solutions… includes developing innovative fertilizers to increase crop yields while decreasing environmental impact, recycling industrial by-products into useful resources, which aligns with several UN SDGs… 2. NextEra Energy (NYSE: NEE) NextEra Energy specializes in harnessing wind and solar energy across North America… Beyond renewable energy, they also engage in physical contracts, trading activities, and marketing. Their primary income source is distributing gas and electricity to Florida residents. 3. Republic Services (NYSE: RSG) Republic Services specializes in waste management and recycling. As the second-largest waste management company in the United States, its mission is to produce renewable energy through recycling.” End quotes. ------------------------------------------------------------- Other Honorable Mentions – not in any order. 1) Title: Vegan investments: Are you putting your money where your mouth is? On veganfoodandliving.com. By Phil Davis. 2) Title: Why Fastenal is a Top Socially Responsible Dividend Stock (FAST) on nasdaq.com. By BNK Invest. 3) Title: 12 Best Solar Energy and Battery Stocks To Buy Now on finance.yahoo.com. By Hamna Asim. 4) Title: Revolutionizing the Future: “Emerging Green Technology Stocks” to Watch Now! – CLNV, GEVO, ADN, HYSR found on digitaljournal.com. By The Street Reports. ------------------------------------------------------------- Ending Comment Well, these are my top news stories with their stock and fund tips -- for this podcast titled: “The Sustainable Stocks The Rich Invest In!” Now, please be sure to click the like and subscribe buttons on Apple Podcasts, Google Podcasts, or wherever you download or listen to this podcast. That helps bring these podcasts to others like you. And please click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope and prosperity in these very troubled times! Contact me if you have any questions. Thank you for listening. Talk to you next on August 11th. And, again, please look at my new totally revised website at investingforthesoul.com! Tell me what you think! Bye for now.   © 2023 Ron Robins, Investing for the Soul

Here's what is happening in the markets today, Thursday, July 13th Stocks higher for 4 days in a row S&P stalls at 4500 PPI Data is out - Are producer prices getting better? Jobless Claims lower than expected Delta (DAL) reports earnings and sees a big reversal PLUS: We'll review Markus' ABBV trade to see if he should be worried and look at our Earnings Analysis Tool to find out what to expect with JPM earnings tomorrow. This wraps up today's stock market news. If you enjoyed the "Stock Market Today" episode, make sure to subscribe to this podcast. And for more stock market news, visit our YouTube Channel: https://youtube.com/rockwelltrading2008 #todaysstockmarket #stockmarkettoday #stockmarket

Welcome to this week's edition of the Financial Insider! Here's what we have lined up for you:

3M had a big run-up at the end of the week due to some news regarding a first settlement of at least 10 billion. Is now the time to buy? We do a bit of a deeper dive into those litigations to really understand if the path is clear for 3M's recovery. What's more in this episode: our thoughts about Target and their #GoWokeGoBroke failure. Does this provide an attractive buying opportunity? Last but not least, many listeners questions ranging from our thoughts about stocks like $LOTB, $JNJ, $ABBV, $ROG to our opinion about whether beating the market should be a dividend growth investors goal. Having said that, it's a jam-packed show, and as always, C U on the inside!

In this episode, we delve into the latest data on bispecific antibodies in multiple myeloma with Dr. Ajai Chari. Here are the key studies discussed:1. Teclistamab (MajesTEC-1 trial): https://pubmed.ncbi.nlm.nih.gov/35661166/2. Correlative analysis from MajesTEC-1 trial: https://ashpublications.org/blood/article/140/Supplement%201/241/4876193.  Talquetamab (MonumenTAL-1 trial): https://pubmed.ncbi.nlm.nih.gov/36507686/4. Phase 1 trial of fixed-duration cevostamab: https://ashpublications.org/blood/article/140/Supplement%201/4415/4923395. Phase 1 trial of ABBV-383: https://pubmed.ncbi.nlm.nih.gov/36029527/6. Paper summarizing infections with different bispecific antibodies in myeloma: https://pubmed.ncbi.nlm.nih.gov/36716411/

For the News of the Week, we started the show by talking about Germany which has now officially entered into a technical recession. As the biggest market in the EU, the market did not overreact to this news. Was it already priced in? Medtronic ($MDT) released full-year results and EDGI gives a brief rundown on the results. The Share price has dropped to 81.50 USD while the company hiked its dividend by 1.5%. Derek questions the dividend safety of the company.  Dividend Increases: Lowe's Companies hikes dividend by 5% Guess hikes the dividend by 33.3%  LyondellBasell Industries hiked the dividend by 5%. Main Topic In the main topic, both EDGI and Derek give 5 points each around what they wish they knew before starting investing.  Key points include Investing regularly is not easy Have a plan and stick to it You cant borrow conviction Dividend Safety Numbers don't lie. Humans do We finish the show with questions from the community where we talk about tickers such as $SBUX, $LIGHT, $JNJ, $ABBV, $VHYL, $WSM  Links mentioned in the show Ep #9 – How we perform fundamental analysis - Dividend Talk  EP #21 – Why the balance sheet of a company is so important to us - Dividend Talk EP #32 – How to spot a company in decline - Dividend Talk  Would you like to support us? Join us on Facebook: https://www.facebook.com/groups/dividendtalk Or if you are interested in buying a nice t-shirt or hoodie with one of your favorite quotes from the dividend talk podcast?  Then check out our Dividend Talk shop:  https://dividendtalk.myspreadshop.ie/

In this video, we'll perform an ABBV stock analysis and figure out what the company looks like based on the numbers. Is Abbvie Inc one of the best Dividend stocks to buy at the current price? Find out in the video above! Global Value's Abbvie Inc stock analysis. Check out Seeking Alpha Premium and score an annual plan for just $119 - that's 50% off! Plus all funds from affiliate referrals go directly towards supporting the channel! Affiliate link - https://www.sahg6dtr.com/H4BHRJ/R74QP/ If you'd like to try Sharesight, please use my referral link to support the channel! https://www.sharesight.com/globalvalue (remember you get 4 months free if you sign up for an annual subscription!) Abbvie Inc ($ABBV) | Abbvie Inc. Stock Value Analysis | Abbvie Inc Stock Dividend Analysis | ABBV Dividend Analysis | $ABBV Dividend Analysis (Recorded August 1, 2022) ❖ MUSIC ❖ ♪ "Lift" Artist: Andy Hu License: Creative Commons Attribution 3.0. ➢ http://creativecommons.org/licenses/b... ➢ https://www.youtube.com/watch?v=sQCuf... 8 Pillar Analysis Props to Everything Money ➢ https://www.youtube.com/c/EverythingMoney

Welcome back to another episode of dividend talk! In today's show we start with discussing the news of the week, i.e. Disney's ($DIS) intention to reinstate the dividend, but also the Search-AI wars ($MSFT $GOOGL) and a mention of Ingredion ($INGR). We then go on to discuss 6 German dividend stocks as the main theme of today ($BAS $DPW $HEI $HBM $COK $MUV2). Some of these are classic choices but we have also a few relatively small companies in there. Last but not least, we're reviewing someone's portfolio and answer several questions of yours. Tickers mentioned are $ENB, $TROW, $KMI, $ABBV, $TRP, $TLX, $HLAG, $CL, $FRE, $BAYN, $BRK, $ALV, $EIN3. Links referenced in the podcast: Dividend Talk YouTube channel: https://www.youtube.com/@DividendTalk Divided Talk Facebook group: https://www.facebook.com/groups/dividendtalk

It doesn't make sense to just focus on profits when you're a human being with other economic interests, says James Katz. He discusses investing in companies that benefit humanity, He examines the Humankind U.S. Stock ETF (HKND), which recently announced its inaugural "Humankind 100" list. Alphabet (GOOGL) topped the list of companies that sustain human well-being. Some other notable companies listed on the "Humankind 100" list include JNJ, PFE, ABBV, VZ, BMY, MRK, LLY, PG, MSFT. Tune in to find out more about the stock market today.

In this JAM PACKED episode, I recap all the Dividends received, stock buys, TWO dividend stock sales, a MERGER with a special dividend, what's up with INTEL, Twitter questions and Who's Trajan?? Stocks mentioned in this episode - TXN, MCD, AOS, MO, IIPR, LEG, MMM, INTC, NSC, UNP, BTI, PEP, WMT, KR, COST, ACI, PG, JNJ, ABBV, INTC Dapper Dividends newsletter SIGNUP FORM Contact - russ@dapperdividends.com Investopedia - What are covered calls? The Official Dapper Dividends Shop! Russ' YouTube video on TEXAS INSTRUMENTS (TXN) The Economist Guide to Analysing Companies Book affiliate link HERE **SPECIAL SEEKINGALPHA.COM offer - $99 for the annual plan. Use this affiliate link and I'll get a few bucks kicked back my way at no additional cost to you- CLICK HERE! WallStreetSurvivor.com "Is Seeking Alpha Worth It?" Why Does The Stock Market Go Up - By Brian Feroldi - (Probably the easiest investing book for an absolute beginner I've ever read). I highly recommend this book for ALL interested in dividend investing, from beginner to advanced - "The Dividend Millionaire" book (The above links are an affiliation where I will receive a small commission at no additional charge to you.) Check my website out - https://dapperdividends.com/ Follow Russ on Twitter - @Rustyram78 Remember this is not financial advice and it's ultimately your money and your responsibility!

Olá Viajante! No episódio #53 do Viajando na Maionese a gente tem uma conversa aberta e sincera sobre como o momento mais tenso para todo viajante: a imigração! Post com as dicas que conversamos nesse episódio: https://viajanterei.com.br/2022/09/02/imigracao/.   Link para a pesquisa ABBV sobre o perfil do viajante: https://www.idealisresearch.com/survey/index.php/259254. Ajude a gente, respondendo à pesquisa até dia 18/09/2022 e divulgue para seus amigos e familiares viajantes. ****************************** Gostou? Quer ajuda para planejar sua próxima viagem? Para falar com a gente é fácil: você pode enviar um WhatsApp por aqui: ⁠http://bit.ly/VR-WA⁠.ou para o número +55(21)97925-4747 ou um e-mail para ⁠contato@viajandonamaionese.com.br⁠. Blog "Viajante Rei": ⁠https://viajanterei.com.br⁠ Viajando na Maionese Podcast: ⁠https://viajandonamaionese.com.br⁠ Os Cursos e Treinamentos recomendados por nós estão disponíveis em: ⁠https://viajanterei.com.br/cursos/⁠. Esperamos que você aproveite o conteúdo e nos vemos no próximo episódio do “Viajando na Maionese”. Até lá, Viajante!

The pros and cons of buying a bunch of blue-chip stocks and holding them for 20+ years. (0:30) - Buy and Never Sell Your Investments (3:45) - Breaking Down The 10 and 20 Year Returns For Stock Market Indexes  (10:15) - Have Any Stocks Outperformed The Indexes? (20:40) - Are Dividend Stocks The Best For Long Term Investing? (26:00) - Episode Roundup: GE, IBM, PFE, ABBV, BMY,  MRK, JNJ, UNH, MCD, SBUX, MSFT Podcast@Zacks.com

Olá Viajante! No episódio #53 do Viajando na Maionese a gente tem uma conversa aberta e sincera sobre como o momento mais tenso para todo viajante: a imigração! Post com as dicas que conversamos nesse episódio: https://viajanterei.com.br/2022/09/02/imigracao/. Link para a pesquisa ABBV sobre o perfil do viajante: https://www.idealisresearch.com/survey/index.php/259254. Ajude a gente, respondendo a pesquisa até dia 18/09/2022 e divulge para seus amigos e familiares viajantes. ****************************** Quer ajuda para planejar sua próxima viagem? Para falar com a gente é fácil: você pode enviar um WhatsApp por aqui http://bit.ly/VR-WA ou para o número +55(21)97925-4747 ou um e-mail para contato@viajandonamaionese.com.br. Esperamos que você aproveite o conteúdo e nos vemos no próximo episódio do “Viajando na Maionese”. Até lá, Viajante! --- Send in a voice message: https://anchor.fm/viajanterei/message

SUPPORT THE PODCAST - https://anchor.fm/dailystockpick/support $LNG $SRE - Nat gas $Uber may be a buy now - josh brown and serrat on cnbc at lunch time have made the case that it's now time to get in to it $Lng with josh brown is saying is the one of the few that can ship lng out of thr us cheaply Corey - insta Also, I don't know if you had a chance to look at $CE, the stock that buffet picked up. (Brand new to his folio). I was curious to see if there's a connection. Mostly speculation at this point but I believe there's a correlation between his buy in $OXY and $CE. $XLE - down again - may be time to take profits on things like $DVN and $OXY $CRWD - beat but the multiple is so high - $PANW lower $BBBY - dilution and no real plan $BABA $APPH $Fcx $Clf $Orcl $Qcom $Spg $Unh $Cost $UPRO - bull $SPXU - bear $SPXL - bull $TQQQ - bull $SQQQ - bear $SARK - bear ENERGY $Cop $Dvn $Oxy $Xom $Cvx $Fang $UCO $SCO $BOIL $KOLD $DE $Qcom $Clf $MRNA $DRV $GS $CGC $TLRY $CRON $MU $CRK $VET $MARA I would be in $PINS not snap - $snap laying off 20% of employees $ABBV is a good example of one that's falling but could be a buy $UNH looking to fill the gap SCANS $Hood - I can't recommend it because as a brokerage it's horrible --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/dailystockpick/support

Simon discusses the recent ebbing of the stock market rally off the June lows. He suggests a trading range might take over where selectivity, discipline, and a heightened focus on fundamentals, particularly free cash flow generation, will increasingly come into play. He brings on Nick to discuss the key takeaways and impacts from the Inflation Reduction Act. Companies mentioned in this episode include MTK, ABBV, GNRC, AAPL, DHR, AMZN, APTV, NN CVX, XOM, and JNJ.

The markets are under pressure ahead of today's FOMC minutes release. Caleb Silver discusses recession indicators to track in today's markets. He talks about how the U.S. dollar (/DX) is near 20-year highs. He then goes over why health care and materials divergence is significant, highlighting IYH, XLB, and XLE. He also notes his stocks to watch which include GILD, ABBV, CAG, and TAP. Finally, he examines the recent rally in 2020 bubble sectors. Tune in to find out more.

"The comparable second half of 1970, the stock market went up 27%. I am not overly bullish, however. The Fed is tightening to kill inflation and to start a recession," says David Darst. He also weighs in on the upcoming corporate earnings. Darst provides his current stocks to buy, which include General Mills (GS), Abbvie (ABBV), and Fifth Third Bancorp (FITB).

Rising interest rates have caused equity valuations to decline moderately, says Austin Graff. He discusses TrueShares Low Volatility Equity Income ETF (DIVZ). He talks about how DIVZ is only down 1% this year and some of its top stock holdings include UNH, JNJ, XOM, ABBV, and DVN. He then forecasts for a potential recession and notes what to expect from the markets in the second half of the year. Tune in to find out more.

The numbers are just going to stay high, says Dan Genter. He discusses the takeaways from the Fed's rate hike decision. He also talks about stock picking in the current market environment, highlighting IBM (IBM). He then goes over his health care stock picks which include Bristol-Myers Squibb (BMY), AbbVie (ABBV), and Medtronic (MDT). Tune in to find out more.

In this episode, we touch on several earnings reports that caught our attention the most. Hence, tune-in to hear about our thoughts and also our answers to the questions from you, the listener. Have a great week ahead!

Austin Graff makes the case for investing in tobacco companies, following the FDA proposing a ban on menthol cigarettes and flavored cigars. He also looks at the TrueShares Low Volatility Equity Income ETF as a more defensive play, with its top holdings consisting of UNH, DVN, JNJ, ABBV, AEP, XOM, MO, PM, WBA, NLOK.